Breaking News

Monday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Conference/Events
Cantor biotech/biopharma analysts hold an analyst/industry conference call » 11:25
06/07/21
06/07
11:25
06/07/21
11:25
AMGN

Amgen

$237.10 /

+0.29 (+0.12%)

, FATE

Fate Therapeutics

$75.38 /

+2.62 (+3.60%)

, GILD

Gilead

$67.47 /

+0.05 (+0.07%)

, KDMN

Kadmon

$4.06 /

+0.2 (+5.18%)

, PBYI

Puma Biotechnology

$11.76 /

+0.48 (+4.26%)

, RCUS

Arcus Biosciences

$25.29 /

+0.16 (+0.64%)

, REGN

Regeneron

$516.17 /

+5.34 (+1.05%)

, JNJ

Johnson & Johnson

$165.82 /

-0.14 (-0.08%)

, PFE

Pfizer

$39.42 /

+0.28 (+0.72%)

, MRK

Merck

$73.44 /

-0.68 (-0.92%)

, LLY

Eli Lilly

$218.17 /

+16.055 (+7.94%)

, IMAB

I-MAB

$75.98 /

-2.02 (-2.59%)

, HCM

Hutchison China MediTech

$30.80 /

+0.72 (+2.39%)

, HTBX

Heat Biologics

$6.80 /

+0.355 (+5.51%)

Biotechnology Analyst…

Biotechnology Analyst Young & Biopharma Analyst Chen, along with KOL Dr. Sabari, Assistant Professor at NYU Langone Medical Center & Dr. Mehta, Physician at Dana-Farber Cancer Institute, discuss novel treatments for lung and breast cancer, as announced at ASCO Annual Virtual Meeting, on an Analyst/Industry conference call to be held on June 7 at 12 pm.

ShowHide Related Items >><<
REGN Regeneron
$516.17 /

+5.34 (+1.05%)

RCUS Arcus Biosciences
$25.29 /

+0.16 (+0.64%)

PFE Pfizer
$39.42 /

+0.28 (+0.72%)

PBYI Puma Biotechnology
$11.76 /

+0.48 (+4.26%)

MRK Merck
$73.44 /

-0.68 (-0.92%)

LLY Eli Lilly
$218.17 /

+16.055 (+7.94%)

KDMN Kadmon
$4.06 /

+0.2 (+5.18%)

JNJ Johnson & Johnson
$165.82 /

-0.14 (-0.08%)

IMAB I-MAB
$75.98 /

-2.02 (-2.59%)

HTBX Heat Biologics
$6.80 /

+0.355 (+5.51%)

HCM Hutchison China MediTech
$30.80 /

+0.72 (+2.39%)

GILD Gilead
$67.47 /

+0.05 (+0.07%)

FATE Fate Therapeutics
$75.38 /

+2.62 (+3.60%)

AMGN Amgen
$237.10 /

+0.29 (+0.12%)

AMGN Amgen
$237.10 /

+0.29 (+0.12%)

06/07/21 SVB Leerink
Amgen price target raised to $238 from $230 at SVB Leerink
06/07/21 Oppenheimer
Amgen price target raised to $277 from $272 at Oppenheimer
05/31/21 BMO Capital
Amgen price target raised to $301 from $296 at BMO Capital
05/28/21 Piper Sandler
Piper says Amgen's Lumakras approved early, priced a bit lower than expected
FATE Fate Therapeutics
$75.38 /

+2.62 (+3.60%)

06/07/21 H.C. Wainwright
Fate Therapeutics upgraded to Buy from Neutral at H.C. Wainwright
06/04/21 Roth Capital
Fate Therapeutics duration response remains unknown, says Roth Capital
06/04/21 Piper Sandler
Fate's Phase I data showed 8 patients achieved ORR, says Piper Sandler
04/26/21 Jefferies
Fate Therapeutics assumed with a Buy at Jefferies
GILD Gilead
$67.47 /

+0.05 (+0.07%)

04/01/21
Fly Intel: Top five analyst upgrades
04/01/21 Bernstein
Gilead upgraded to Outperform from Market Perform at Bernstein
03/30/21 Redburn
Gilead upgraded to Buy from Neutral at Redburn
03/15/21 Mizuho
Merck's Gilead collaboration likely to broaden reach of islatravir, says Mizuho
KDMN Kadmon
$4.06 /

+0.2 (+5.18%)

06/04/21 Mizuho
Kadmon's KD022 results a positive start for immuno-oncology program, says Mizuho
05/20/21 UBS
Kadmon initiated with a Buy at UBS
03/11/21 Oppenheimer
Kadmon should be bought on weakness from FDA extension, says Oppenheimer
02/10/21 Jefferies
Survey points to 'encouraging' signs for Kadmon's belumosudil, says Jefferies
PBYI Puma Biotechnology
$11.76 /

+0.48 (+4.26%)

12/24/20 Craig-Hallum
Celcuity price target raised to $19 from $16 at Craig-Hallum
06/25/20 BofA
Puma Biotechnology reinstated with an Underperform at BofA
06/25/20 BofA
Puma Biotechnology initiated with an Underperform at BofA
RCUS Arcus Biosciences
$25.29 /

+0.16 (+0.64%)

02/25/21 Barclays
Arcus Biosciences price target raised to $45 from $40 at Barclays
02/25/21 Mizuho
Arcus Biosciences price target raised to $43 from $40 at Mizuho
01/20/21 Citi
Arcus Biosciences price target raised to $51 from $32 at Citi
01/19/21 Wedbush
Arcus Biosciences price target raised to $55 from $48 at Wedbush
REGN Regeneron
$516.17 /

+5.34 (+1.05%)

05/13/21 Needham
Graybug Vision downgraded to Hold from Buy at Needham
05/07/21 Morgan Stanley
Regeneron price target raised to $495 from $477 at Morgan Stanley
05/06/21 Piper Sandler
Regeneron remains top large cap pick, says Piper Sandler
04/12/21 Benchmark
Benchmark sees full FDA approval of Regeneron's REGEN-COV coming
JNJ Johnson & Johnson
$165.82 /

-0.14 (-0.08%)

06/02/21 Jefferies
Legend Biotech cilta-cel PFS rate 'largely exceeds' expectation, says Jefferies
05/28/21
Fly Intel: Top five analyst initiations
05/28/21 Morgan Stanley
Johnson & Johnson assumed with an Overweight at Morgan Stanley
05/05/21 Argus
Emergent BioSolutions downgraded to Hold from Buy at Argus
PFE Pfizer
$39.42 /

+0.28 (+0.72%)

06/01/21 Argus
Argus says market underestimating sustainability of Pfizer COVID vaccine program
05/18/21 William Blair
William Blair says continued lack of '9001 safety signals positive for Sarepta
05/12/21 Canaccord
BioNTech price target raised to $240 from $130 at Canaccord
05/11/21 SVB Leerink
BioNTech price target raised to $159 from $118 at SVB Leerink
MRK Merck
$73.44 /

-0.68 (-0.92%)

06/07/21 Truist
Merck price target lowered to $93 from $96 at Truist
05/20/21
Fly Intel: Top five analyst downgrades
05/20/21 Argus
Merck downgraded to Hold at Argus ahead of Organon spinoff
05/20/21 Argus
Merck downgraded to Hold from Buy at Argus
LLY Eli Lilly
$218.17 /

+16.055 (+7.94%)

05/27/21 H.C. Wainwright
H.C. Wainwright bullish on Dicerna as new RNAi candidate enters clinic
05/24/21 H.C. Wainwright
Aurinia reported positive data as competitors 'stumble,' says H.C. Wainwright
04/28/21 Mizuho
Eli Lilly price target lowered to $216 from $228 at Mizuho
04/28/21 Barclays
Eli Lilly price target lowered to $227 from $232 at Barclays
IMAB I-MAB
$75.98 /

-2.02 (-2.59%)

06/07/21 Piper Sandler
I-MAB price target raised to $90 from $75 at Piper Sandler
06/02/21 Daiwa
I-MAB initiated with a Buy at Daiwa
03/15/21 Needham
I-MAB initiated with a Buy at Needham
03/03/21 H.C. Wainwright
I-MAB price target raised to $75 from $55 at H.C. Wainwright
HCM Hutchison China MediTech
$30.80 /

+0.72 (+2.39%)

10/02/20 Deutsche Bank
Hutchison China MediTech initiated with a Buy at Deutsche Bank
HTBX Heat Biologics
$6.80 /

+0.355 (+5.51%)

05/06/21 Alliance Global Partners
Heat Biologics price target lowered to $32 from $40 at Alliance Global Partners
03/02/21 Cantor Fitzgerald
Heat Biologics initiated with an Overweight at Cantor Fitzgerald
02/09/21 Alliance Global Partners
Heat Biologics price target raised to $40 from $5 at Alliance Global Partners
02/09/21 Maxim
Heat data puts cancer vaccine discussion 'back on the table,' says Maxim
REGN Regeneron
$516.17 /

+5.34 (+1.05%)

RCUS Arcus Biosciences
$25.29 /

+0.16 (+0.64%)

PFE Pfizer
$39.42 /

+0.28 (+0.72%)

PBYI Puma Biotechnology
$11.76 /

+0.48 (+4.26%)

MRK Merck
$73.44 /

-0.68 (-0.92%)

LLY Eli Lilly
$218.17 /

+16.055 (+7.94%)

JNJ Johnson & Johnson
$165.82 /

-0.14 (-0.08%)

HTBX Heat Biologics
$6.80 /

+0.355 (+5.51%)

HCM Hutchison China MediTech
$30.80 /

+0.72 (+2.39%)

GILD Gilead
$67.47 /

+0.05 (+0.07%)

FATE Fate Therapeutics
$75.38 /

+2.62 (+3.60%)

AMGN Amgen
$237.10 /

+0.29 (+0.12%)

  • 09
    Feb
  • 13
    Jan
  • 06
    Jan
  • 09
    Jun
REGN Regeneron
$516.17 /

+5.34 (+1.05%)

PFE Pfizer
$39.42 /

+0.28 (+0.72%)

MRK Merck
$73.44 /

-0.68 (-0.92%)

LLY Eli Lilly
$218.17 /

+16.055 (+7.94%)

JNJ Johnson & Johnson
$165.82 /

-0.14 (-0.08%)

GILD Gilead
$67.47 /

+0.05 (+0.07%)

AMGN Amgen
$237.10 /

+0.29 (+0.12%)

REGN Regeneron
$516.17 /

+5.34 (+1.05%)

PFE Pfizer
$39.42 /

+0.28 (+0.72%)

MRK Merck
$73.44 /

-0.68 (-0.92%)

LLY Eli Lilly
$218.17 /

+16.055 (+7.94%)

KDMN Kadmon
$4.06 /

+0.2 (+5.18%)

JNJ Johnson & Johnson
$165.82 /

-0.14 (-0.08%)

HTBX Heat Biologics
$6.80 /

+0.355 (+5.51%)

GILD Gilead
$67.47 /

+0.05 (+0.07%)

FATE Fate Therapeutics
$75.38 /

+2.62 (+3.60%)

AMGN Amgen
$237.10 /

+0.29 (+0.12%)

REGN Regeneron
$516.17 /

+5.34 (+1.05%)

PFE Pfizer
$39.42 /

+0.28 (+0.72%)

MRK Merck
$73.44 /

-0.68 (-0.92%)

LLY Eli Lilly
$218.17 /

+16.055 (+7.94%)

JNJ Johnson & Johnson
$165.82 /

-0.14 (-0.08%)

IMAB I-MAB
$75.98 /

-2.02 (-2.59%)

HTBX Heat Biologics
$6.80 /

+0.355 (+5.51%)

HCM Hutchison China MediTech
$30.80 /

+0.72 (+2.39%)

GILD Gilead
$67.47 /

+0.05 (+0.07%)

AMGN Amgen
$237.10 /

+0.29 (+0.12%)

Conference/Events
Cantor biotech/biopharma analysts hold an analyst/industry conference call » 04:55
06/07/21
06/07
04:55
06/07/21
04:55
AMGN

Amgen

$236.83 /

+1.09 (+0.46%)

, FATE

Fate Therapeutics

$72.96 /

+5.63 (+8.36%)

, GILD

Gilead

$67.42 /

+0.94 (+1.41%)

, KDMN

Kadmon

$3.86 /

+0.08 (+2.12%)

, PBYI

Puma Biotechnology

$11.28 /

+0.45 (+4.16%)

, RCUS

Arcus Biosciences

$25.05 /

+0.2 (+0.80%)

, REGN

Regeneron

$511.44 /

+5.22 (+1.03%)

, JNJ

Johnson & Johnson

$165.94 /

-0.09 (-0.05%)

, PFE

Pfizer

$39.14 /

+0.165 (+0.42%)

, MRK

Merck

$74.12 /

+0.22 (+0.30%)

, LLY

Eli Lilly

$202.05 /

-0.62 (-0.31%)

, IMAB

I-MAB

$77.97 /

+1.94 (+2.55%)

, HCM

Hutchison China MediTech

$30.08 /

-0.28 (-0.92%)

, HTBX

Heat Biologics

$6.46 /

-0.12 (-1.82%)

Biotechnology Analyst…

Biotechnology Analyst Young & Biopharma Analyst Chen, along with KOL Dr. Sabari, Assistant Professor at NYU Langone Medical Center & Dr. Mehta, Physician at Dana-Farber Cancer Institute, discuss novel treatments for lung and breast cancer, as announced at ASCO Annual Virtual Meeting, on an Analyst/Industry conference call to be held on June 7 at 12 pm.

ShowHide Related Items >><<
REGN Regeneron
$511.44 /

+5.22 (+1.03%)

RCUS Arcus Biosciences
$25.05 /

+0.2 (+0.80%)

PFE Pfizer
$39.14 /

+0.165 (+0.42%)

PBYI Puma Biotechnology
$11.28 /

+0.45 (+4.16%)

MRK Merck
$74.12 /

+0.22 (+0.30%)

LLY Eli Lilly
$202.05 /

-0.62 (-0.31%)

KDMN Kadmon
$3.86 /

+0.08 (+2.12%)

JNJ Johnson & Johnson
$165.94 /

-0.09 (-0.05%)

IMAB I-MAB
$77.97 /

+1.94 (+2.55%)

HTBX Heat Biologics
$6.46 /

-0.12 (-1.82%)

HCM Hutchison China MediTech
$30.08 /

-0.28 (-0.92%)

GILD Gilead
$67.42 /

+0.94 (+1.41%)

FATE Fate Therapeutics
$72.96 /

+5.63 (+8.36%)

AMGN Amgen
$236.83 /

+1.09 (+0.46%)

AMGN Amgen
$236.83 /

+1.09 (+0.46%)

05/31/21 BMO Capital
Amgen price target raised to $301 from $296 at BMO Capital
05/28/21 Piper Sandler
Piper says Amgen's Lumakras approved early, priced a bit lower than expected
05/03/21 Oppenheimer
Amgen price target lowered to $265 from $275 at Oppenheimer
04/28/21 Atlantic Equities
Amgen downgraded to Underweight from Neutral at Atlantic Equities
FATE Fate Therapeutics
$72.96 /

+5.63 (+8.36%)

06/04/21 Roth Capital
Fate Therapeutics duration response remains unknown, says Roth Capital
06/04/21 Piper Sandler
Fate's Phase I data showed 8 patients achieved ORR, says Piper Sandler
04/26/21 Jefferies
Fate Therapeutics assumed with a Buy at Jefferies
03/04/21 Wells Fargo
Fate Therapeutics price target raised to $130 from $84 at Wells Fargo
GILD Gilead
$67.42 /

+0.94 (+1.41%)

04/01/21
Fly Intel: Top five analyst upgrades
04/01/21 Bernstein
Gilead upgraded to Outperform from Market Perform at Bernstein
03/30/21 Redburn
Gilead upgraded to Buy from Neutral at Redburn
03/15/21 Mizuho
Merck's Gilead collaboration likely to broaden reach of islatravir, says Mizuho
KDMN Kadmon
$3.86 /

+0.08 (+2.12%)

06/04/21 Mizuho
Kadmon's KD022 results a positive start for immuno-oncology program, says Mizuho
05/20/21 UBS
Kadmon initiated with a Buy at UBS
03/11/21 Oppenheimer
Kadmon should be bought on weakness from FDA extension, says Oppenheimer
02/10/21 Jefferies
Survey points to 'encouraging' signs for Kadmon's belumosudil, says Jefferies
PBYI Puma Biotechnology
$11.28 /

+0.45 (+4.16%)

12/24/20 Craig-Hallum
Celcuity price target raised to $19 from $16 at Craig-Hallum
06/25/20 BofA
Puma Biotechnology reinstated with an Underperform at BofA
06/25/20 BofA
Puma Biotechnology initiated with an Underperform at BofA
RCUS Arcus Biosciences
$25.05 /

+0.2 (+0.80%)

02/25/21 Barclays
Arcus Biosciences price target raised to $45 from $40 at Barclays
02/25/21 Mizuho
Arcus Biosciences price target raised to $43 from $40 at Mizuho
01/20/21 Citi
Arcus Biosciences price target raised to $51 from $32 at Citi
01/19/21 Wedbush
Arcus Biosciences price target raised to $55 from $48 at Wedbush
REGN Regeneron
$511.44 /

+5.22 (+1.03%)

05/13/21 Needham
Graybug Vision downgraded to Hold from Buy at Needham
05/07/21 Morgan Stanley
Regeneron price target raised to $495 from $477 at Morgan Stanley
05/06/21 Piper Sandler
Regeneron remains top large cap pick, says Piper Sandler
04/12/21 Benchmark
Benchmark sees full FDA approval of Regeneron's REGEN-COV coming
JNJ Johnson & Johnson
$165.94 /

-0.09 (-0.05%)

06/02/21 Jefferies
Legend Biotech cilta-cel PFS rate 'largely exceeds' expectation, says Jefferies
05/28/21
Fly Intel: Top five analyst initiations
05/28/21 Morgan Stanley
Johnson & Johnson assumed with an Overweight at Morgan Stanley
05/05/21 Argus
Emergent BioSolutions downgraded to Hold from Buy at Argus
PFE Pfizer
$39.14 /

+0.165 (+0.42%)

06/01/21 Argus
Argus says market underestimating sustainability of Pfizer COVID vaccine program
05/18/21 William Blair
William Blair says continued lack of '9001 safety signals positive for Sarepta
05/12/21 Canaccord
BioNTech price target raised to $240 from $130 at Canaccord
05/11/21 SVB Leerink
BioNTech price target raised to $159 from $118 at SVB Leerink
MRK Merck
$74.12 /

+0.22 (+0.30%)

05/20/21
Fly Intel: Top five analyst downgrades
05/20/21 Argus
Merck downgraded to Hold at Argus ahead of Organon spinoff
05/20/21 Argus
Merck downgraded to Hold from Buy at Argus
05/05/21 BTIG
Mereo BioPharma initiated with a Buy at BTIG
LLY Eli Lilly
$202.05 /

-0.62 (-0.31%)

05/27/21 H.C. Wainwright
H.C. Wainwright bullish on Dicerna as new RNAi candidate enters clinic
05/24/21 H.C. Wainwright
Aurinia reported positive data as competitors 'stumble,' says H.C. Wainwright
04/28/21 Mizuho
Eli Lilly price target lowered to $216 from $228 at Mizuho
04/28/21 Barclays
Eli Lilly price target lowered to $227 from $232 at Barclays
IMAB I-MAB
$77.97 /

+1.94 (+2.55%)

06/02/21 Daiwa
I-MAB initiated with a Buy at Daiwa
03/15/21 Needham
I-MAB initiated with a Buy at Needham
03/03/21 H.C. Wainwright
I-MAB price target raised to $75 from $55 at H.C. Wainwright
02/25/21
Fly Intel: Top five analyst initiations
HCM Hutchison China MediTech
$30.08 /

-0.28 (-0.92%)

10/02/20 Deutsche Bank
Hutchison China MediTech initiated with a Buy at Deutsche Bank
HTBX Heat Biologics
$6.46 /

-0.12 (-1.82%)

05/06/21 Alliance Global Partners
Heat Biologics price target lowered to $32 from $40 at Alliance Global Partners
03/02/21 Cantor Fitzgerald
Heat Biologics initiated with an Overweight at Cantor Fitzgerald
02/09/21 Alliance Global Partners
Heat Biologics price target raised to $40 from $5 at Alliance Global Partners
02/09/21 Maxim
Heat data puts cancer vaccine discussion 'back on the table,' says Maxim
REGN Regeneron
$511.44 /

+5.22 (+1.03%)

RCUS Arcus Biosciences
$25.05 /

+0.2 (+0.80%)

PFE Pfizer
$39.14 /

+0.165 (+0.42%)

PBYI Puma Biotechnology
$11.28 /

+0.45 (+4.16%)

MRK Merck
$74.12 /

+0.22 (+0.30%)

LLY Eli Lilly
$202.05 /

-0.62 (-0.31%)

JNJ Johnson & Johnson
$165.94 /

-0.09 (-0.05%)

HTBX Heat Biologics
$6.46 /

-0.12 (-1.82%)

HCM Hutchison China MediTech
$30.08 /

-0.28 (-0.92%)

GILD Gilead
$67.42 /

+0.94 (+1.41%)

FATE Fate Therapeutics
$72.96 /

+5.63 (+8.36%)

AMGN Amgen
$236.83 /

+1.09 (+0.46%)

  • 09
    Feb
  • 13
    Jan
  • 06
    Jan
  • 09
    Jun
REGN Regeneron
$511.44 /

+5.22 (+1.03%)

PFE Pfizer
$39.14 /

+0.165 (+0.42%)

MRK Merck
$74.12 /

+0.22 (+0.30%)

LLY Eli Lilly
$202.05 /

-0.62 (-0.31%)

JNJ Johnson & Johnson
$165.94 /

-0.09 (-0.05%)

GILD Gilead
$67.42 /

+0.94 (+1.41%)

AMGN Amgen
$236.83 /

+1.09 (+0.46%)

REGN Regeneron
$511.44 /

+5.22 (+1.03%)

PFE Pfizer
$39.14 /

+0.165 (+0.42%)

MRK Merck
$74.12 /

+0.22 (+0.30%)

LLY Eli Lilly
$202.05 /

-0.62 (-0.31%)

KDMN Kadmon
$3.86 /

+0.08 (+2.12%)

JNJ Johnson & Johnson
$165.94 /

-0.09 (-0.05%)

HTBX Heat Biologics
$6.46 /

-0.12 (-1.82%)

GILD Gilead
$67.42 /

+0.94 (+1.41%)

FATE Fate Therapeutics
$72.96 /

+5.63 (+8.36%)

AMGN Amgen
$236.83 /

+1.09 (+0.46%)

REGN Regeneron
$511.44 /

+5.22 (+1.03%)

PFE Pfizer
$39.14 /

+0.165 (+0.42%)

MRK Merck
$74.12 /

+0.22 (+0.30%)

LLY Eli Lilly
$202.05 /

-0.62 (-0.31%)

JNJ Johnson & Johnson
$165.94 /

-0.09 (-0.05%)

IMAB I-MAB
$77.97 /

+1.94 (+2.55%)

HTBX Heat Biologics
$6.46 /

-0.12 (-1.82%)

HCM Hutchison China MediTech
$30.08 /

-0.28 (-0.92%)

GILD Gilead
$67.42 /

+0.94 (+1.41%)

AMGN Amgen
$236.83 /

+1.09 (+0.46%)

Over a week ago
Conference/Events
Cantor biotech/biopharma analysts hold an analyst/industry conference call » 12:01
06/04/21
06/04
12:01
06/04/21
12:01
AMGN

Amgen

$238.27 /

+2.53 (+1.07%)

, FATE

Fate Therapeutics

$72.52 /

+5.19 (+7.71%)

, GILD

Gilead

$67.43 /

+0.95 (+1.43%)

, KDMN

Kadmon

$3.86 /

+0.08 (+2.12%)

, PBYI

Puma Biotechnology

$11.15 /

+0.32 (+2.95%)

, RCUS

Arcus Biosciences

$25.07 /

+0.22 (+0.89%)

, REGN

Regeneron

$514.71 /

+8.49 (+1.68%)

, JNJ

Johnson & Johnson

$167.32 /

+1.29 (+0.78%)

, PFE

Pfizer

$39.33 /

+0.355 (+0.91%)

, MRK

Merck

$74.26 /

+0.36 (+0.49%)

, LLY

Eli Lilly

$203.62 /

+0.95 (+0.47%)

, IMAB

I-MAB

$79.02 /

+2.99 (+3.93%)

, HCM

Hutchison China MediTech

$29.99 /

-0.37 (-1.22%)

, HTBX

Heat Biologics

$6.50 /

-0.08 (-1.22%)

Biotechnology Analyst…

Biotechnology Analyst Young & Biopharma Analyst Chen, along with KOL Dr. Sabari, Assistant Professor at NYU Langone Medical Center & Dr. Mehta, Physician at Dana-Farber Cancer Institute, discuss novel treatments for lung and breast cancer, as announced at ASCO Annual Virtual Meeting, on an Analyst/Industry conference call to be held on June 7 at 12 pm.

ShowHide Related Items >><<
REGN Regeneron
$514.71 /

+8.49 (+1.68%)

RCUS Arcus Biosciences
$25.07 /

+0.22 (+0.89%)

PFE Pfizer
$39.33 /

+0.355 (+0.91%)

PBYI Puma Biotechnology
$11.15 /

+0.32 (+2.95%)

MRK Merck
$74.26 /

+0.36 (+0.49%)

LLY Eli Lilly
$203.62 /

+0.95 (+0.47%)

KDMN Kadmon
$3.86 /

+0.08 (+2.12%)

JNJ Johnson & Johnson
$167.32 /

+1.29 (+0.78%)

IMAB I-MAB
$79.02 /

+2.99 (+3.93%)

HTBX Heat Biologics
$6.50 /

-0.08 (-1.22%)

HCM Hutchison China MediTech
$29.99 /

-0.37 (-1.22%)

GILD Gilead
$67.43 /

+0.95 (+1.43%)

FATE Fate Therapeutics
$72.52 /

+5.19 (+7.71%)

AMGN Amgen
$238.27 /

+2.53 (+1.07%)

AMGN Amgen
$238.27 /

+2.53 (+1.07%)

05/31/21 BMO Capital
Amgen price target raised to $301 from $296 at BMO Capital
05/28/21 Piper Sandler
Piper says Amgen's Lumakras approved early, priced a bit lower than expected
05/03/21 Oppenheimer
Amgen price target lowered to $265 from $275 at Oppenheimer
04/28/21 Atlantic Equities
Amgen downgraded to Underweight from Neutral at Atlantic Equities
FATE Fate Therapeutics
$72.52 /

+5.19 (+7.71%)

06/04/21 Roth Capital
Fate Therapeutics duration response remains unknown, says Roth Capital
06/04/21 Piper Sandler
Fate's Phase I data showed 8 patients achieved ORR, says Piper Sandler
04/26/21 Jefferies
Fate Therapeutics assumed with a Buy at Jefferies
03/04/21 Wells Fargo
Fate Therapeutics price target raised to $130 from $84 at Wells Fargo
GILD Gilead
$67.43 /

+0.95 (+1.43%)

04/01/21
Fly Intel: Top five analyst upgrades
04/01/21 Bernstein
Gilead upgraded to Outperform from Market Perform at Bernstein
03/30/21 Redburn
Gilead upgraded to Buy from Neutral at Redburn
03/15/21 Mizuho
Merck's Gilead collaboration likely to broaden reach of islatravir, says Mizuho
KDMN Kadmon
$3.86 /

+0.08 (+2.12%)

06/04/21 Mizuho
Kadmon's KD022 results a positive start for immuno-oncology program, says Mizuho
05/20/21 UBS
Kadmon initiated with a Buy at UBS
03/11/21 Oppenheimer
Kadmon should be bought on weakness from FDA extension, says Oppenheimer
02/10/21 Jefferies
Survey points to 'encouraging' signs for Kadmon's belumosudil, says Jefferies
PBYI Puma Biotechnology
$11.15 /

+0.32 (+2.95%)

12/24/20 Craig-Hallum
Celcuity price target raised to $19 from $16 at Craig-Hallum
06/25/20 BofA
Puma Biotechnology reinstated with an Underperform at BofA
06/25/20 BofA
Puma Biotechnology initiated with an Underperform at BofA
RCUS Arcus Biosciences
$25.07 /

+0.22 (+0.89%)

02/25/21 Barclays
Arcus Biosciences price target raised to $45 from $40 at Barclays
02/25/21 Mizuho
Arcus Biosciences price target raised to $43 from $40 at Mizuho
01/20/21 Citi
Arcus Biosciences price target raised to $51 from $32 at Citi
01/19/21 Wedbush
Arcus Biosciences price target raised to $55 from $48 at Wedbush
REGN Regeneron
$514.71 /

+8.49 (+1.68%)

05/13/21 Needham
Graybug Vision downgraded to Hold from Buy at Needham
05/07/21 Morgan Stanley
Regeneron price target raised to $495 from $477 at Morgan Stanley
05/06/21 Piper Sandler
Regeneron remains top large cap pick, says Piper Sandler
04/12/21 Benchmark
Benchmark sees full FDA approval of Regeneron's REGEN-COV coming
JNJ Johnson & Johnson
$167.32 /

+1.29 (+0.78%)

06/02/21 Jefferies
Legend Biotech cilta-cel PFS rate 'largely exceeds' expectation, says Jefferies
05/28/21
Fly Intel: Top five analyst initiations
05/28/21 Morgan Stanley
Johnson & Johnson assumed with an Overweight at Morgan Stanley
05/05/21 Argus
Emergent BioSolutions downgraded to Hold from Buy at Argus
PFE Pfizer
$39.33 /

+0.355 (+0.91%)

06/01/21 Argus
Argus says market underestimating sustainability of Pfizer COVID vaccine program
05/18/21 William Blair
William Blair says continued lack of '9001 safety signals positive for Sarepta
05/12/21 Canaccord
BioNTech price target raised to $240 from $130 at Canaccord
05/11/21 SVB Leerink
BioNTech price target raised to $159 from $118 at SVB Leerink
MRK Merck
$74.26 /

+0.36 (+0.49%)

05/20/21
Fly Intel: Top five analyst downgrades
05/20/21 Argus
Merck downgraded to Hold at Argus ahead of Organon spinoff
05/20/21 Argus
Merck downgraded to Hold from Buy at Argus
05/05/21 BTIG
Mereo BioPharma initiated with a Buy at BTIG
LLY Eli Lilly
$203.62 /

+0.95 (+0.47%)

05/27/21 H.C. Wainwright
H.C. Wainwright bullish on Dicerna as new RNAi candidate enters clinic
05/24/21 H.C. Wainwright
Aurinia reported positive data as competitors 'stumble,' says H.C. Wainwright
04/28/21 Mizuho
Eli Lilly price target lowered to $216 from $228 at Mizuho
04/28/21 Barclays
Eli Lilly price target lowered to $227 from $232 at Barclays
IMAB I-MAB
$79.02 /

+2.99 (+3.93%)

06/02/21 Daiwa
I-MAB initiated with a Buy at Daiwa
03/15/21 Needham
I-MAB initiated with a Buy at Needham
03/03/21 H.C. Wainwright
I-MAB price target raised to $75 from $55 at H.C. Wainwright
02/25/21
Fly Intel: Top five analyst initiations
HCM Hutchison China MediTech
$29.99 /

-0.37 (-1.22%)

10/02/20 Deutsche Bank
Hutchison China MediTech initiated with a Buy at Deutsche Bank
HTBX Heat Biologics
$6.50 /

-0.08 (-1.22%)

05/06/21 Alliance Global Partners
Heat Biologics price target lowered to $32 from $40 at Alliance Global Partners
03/02/21 Cantor Fitzgerald
Heat Biologics initiated with an Overweight at Cantor Fitzgerald
02/09/21 Alliance Global Partners
Heat Biologics price target raised to $40 from $5 at Alliance Global Partners
02/09/21 Maxim
Heat data puts cancer vaccine discussion 'back on the table,' says Maxim
REGN Regeneron
$514.71 /

+8.49 (+1.68%)

RCUS Arcus Biosciences
$25.07 /

+0.22 (+0.89%)

PFE Pfizer
$39.33 /

+0.355 (+0.91%)

PBYI Puma Biotechnology
$11.15 /

+0.32 (+2.95%)

MRK Merck
$74.26 /

+0.36 (+0.49%)

LLY Eli Lilly
$203.62 /

+0.95 (+0.47%)

JNJ Johnson & Johnson
$167.32 /

+1.29 (+0.78%)

HTBX Heat Biologics
$6.50 /

-0.08 (-1.22%)

HCM Hutchison China MediTech
$29.99 /

-0.37 (-1.22%)

GILD Gilead
$67.43 /

+0.95 (+1.43%)

FATE Fate Therapeutics
$72.52 /

+5.19 (+7.71%)

AMGN Amgen
$238.27 /

+2.53 (+1.07%)

  • 09
    Feb
  • 13
    Jan
  • 06
    Jan
  • 09
    Jun
REGN Regeneron
$514.71 /

+8.49 (+1.68%)

PFE Pfizer
$39.33 /

+0.355 (+0.91%)

MRK Merck
$74.26 /

+0.36 (+0.49%)

LLY Eli Lilly
$203.62 /

+0.95 (+0.47%)

JNJ Johnson & Johnson
$167.32 /

+1.29 (+0.78%)

GILD Gilead
$67.43 /

+0.95 (+1.43%)

AMGN Amgen
$238.27 /

+2.53 (+1.07%)

REGN Regeneron
$514.71 /

+8.49 (+1.68%)

PFE Pfizer
$39.33 /

+0.355 (+0.91%)

MRK Merck
$74.26 /

+0.36 (+0.49%)

LLY Eli Lilly
$203.62 /

+0.95 (+0.47%)

KDMN Kadmon
$3.86 /

+0.08 (+2.12%)

JNJ Johnson & Johnson
$167.32 /

+1.29 (+0.78%)

HTBX Heat Biologics
$6.50 /

-0.08 (-1.22%)

GILD Gilead
$67.43 /

+0.95 (+1.43%)

FATE Fate Therapeutics
$72.52 /

+5.19 (+7.71%)

AMGN Amgen
$238.27 /

+2.53 (+1.07%)

REGN Regeneron
$514.71 /

+8.49 (+1.68%)

PFE Pfizer
$39.33 /

+0.355 (+0.91%)

MRK Merck
$74.26 /

+0.36 (+0.49%)

LLY Eli Lilly
$203.62 /

+0.95 (+0.47%)

JNJ Johnson & Johnson
$167.32 /

+1.29 (+0.78%)

IMAB I-MAB
$79.02 /

+2.99 (+3.93%)

HTBX Heat Biologics
$6.50 /

-0.08 (-1.22%)

HCM Hutchison China MediTech
$29.99 /

-0.37 (-1.22%)

GILD Gilead
$67.43 /

+0.95 (+1.43%)

AMGN Amgen
$238.27 /

+2.53 (+1.07%)

Over a month ago
Earnings
Puma Biotechnology reports Q1 EPS 40c, consensus 9c » 16:37
05/06/21
05/06
16:37
05/06/21
16:37
PBYI

Puma Biotechnology

$9.60 /

-0.04 (-0.41%)

Reports Q1 revenue…

Reports Q1 revenue $98.2M, consensus $71.47M. "During the first quarter, we continued to face the challenges brought about by the COVID-19 pandemic and the reduction in commercial access caused by it," said Alan H. Auerbach, CEO. "We are hopeful that with the progress made with vaccinations, commercial access will improve in 2021 which will greatly aid our commercial abilities. We continue to remain focused on and committed to providing support to patients battling cancer. In terms of clinical development, we are pleased that during the first quarter we were able to achieve the completion of enrollment in the randomized cohorts of the Phase II SUMMIT trial of neratinib for patients with hormone receptor-positive breast cancer that has a HER2 mutation. Enrollment in the other cohorts in SUMMIT continued as well, including for patients with EGFR exon 18 mutated non-small cell lung cancer and HER2 mutated cervical cancer. Additionally, our global partners continued to launch NERLYNX in several new countries during the first quarter and we look forward to launches in additional countries throughout 2021."

ShowHide Related Items >><<
PBYI Puma Biotechnology
$9.60 /

-0.04 (-0.41%)

PBYI Puma Biotechnology
$9.60 /

-0.04 (-0.41%)

12/24/20 Craig-Hallum
Celcuity price target raised to $19 from $16 at Craig-Hallum
06/25/20 BofA
Puma Biotechnology reinstated with an Underperform at BofA
06/25/20 BofA
Puma Biotechnology initiated with an Underperform at BofA
05/20/20 Cantor Fitzgerald
Puma Biotechnology price target raised to $16 from $14 at Cantor Fitzgerald
PBYI Puma Biotechnology
$9.60 /

-0.04 (-0.41%)

Over a quarter ago
Hot Stocks
Puma Biotechnology, CANbridge Pharma terminate NERLYNX license agreement » 18:25
02/25/21
02/25
18:25
02/25/21
18:25
PBYI

Puma Biotechnology

$10.62 /

-0.655 (-5.81%)

CANbridge Pharmaceuticals…

CANbridge Pharmaceuticals and Puma Biotechnology have agreed to terminate their 2018 license agreement, in which Puma granted CANbridge exclusive rights to develop and commercialize NERLYNX in Greater China, and to settle their arbitration related to the license agreement. Simultaneous to the termination of the 2018 license agreement between CANbridge and Puma, Puma has agreed with Pierre Fabre, a global pharmaceutical and healthcare products company, to amend the terms of their 2019 license agreement, which grants Pierre Fabre exclusive rights to develop and commercialize NERLYNX within Europe, Turkey, Middle East and Africa, to also include Greater China, which includes mainland China, Taiwan, Hong Kong and Macau. CANbridge and Pierre Fabre have also simultaneously entered into agreements pursuant to which CANbridge will provide Pierre Fabre certain transition services in Greater China and distribute and market NERLYNX for Pierre Fabre in Hong Kong, Macau, and Taiwan until year end 2022, with an option to renew. Under the terms of the various agreements implementing this transaction among the three companies, Puma will receive an upfront payment of $50M from Pierre Fabre in consideration for the amendment to their 2019 license agreement, and CANbridge will receive a one-time $20M termination fee from Puma to return all rights to neratinib in Greater China back to Puma. Finally, Puma has agreed to dismiss the arbitration demand it filed on July 28, 2020 against CANbridge related to the parties' 2018 license agreement, and as part of the settlement, CANbridge has agreed to dismiss its counterclaims against Puma.

ShowHide Related Items >><<
PBYI Puma Biotechnology
$10.62 /

-0.655 (-5.81%)

PBYI Puma Biotechnology
$10.62 /

-0.655 (-5.81%)

12/24/20 Craig-Hallum
Celcuity price target raised to $19 from $16 at Craig-Hallum
06/25/20 BofA
Puma Biotechnology reinstated with an Underperform at BofA
06/25/20 BofA
Puma Biotechnology initiated with an Underperform at BofA
05/20/20 Cantor Fitzgerald
Puma Biotechnology price target raised to $16 from $14 at Cantor Fitzgerald
PBYI Puma Biotechnology
$10.62 /

-0.655 (-5.81%)

Hot Stocks
Puma Biotechnology, Pierre Fabre amend Nerlynx license deal to include China » 16:38
02/25/21
02/25
16:38
02/25/21
16:38
PBYI

Puma Biotechnology

$10.62 /

-0.655 (-5.81%)

Puma Biotechnology and…

Puma Biotechnology and Pierre Fabre have agreed to extend the terms of the 2019 license agreement which grants Pierre Fabre exclusive rights to develop and commercialize NERLYNX(R) within Europe, Turkey, Middle East and Africa. The amended agreement extends Pierre Fabre's commercial rights for NERLYNX to Greater China, which includes mainland China, Taiwan, Hong Kong and Macau. Under the terms of the amendment, Puma will receive an upfront payment of $50M, as well as additional regulatory and sales-based milestone payments that could add up to an additional $240M. These milestones will be based solely on regulatory and sales achievements in Greater China. In addition, Puma will receive significant double-digit tiered royalties on the sales of NERLYNX in Greater China.

ShowHide Related Items >><<
PBYI Puma Biotechnology
$10.62 /

-0.655 (-5.81%)

PBYI Puma Biotechnology
$10.62 /

-0.655 (-5.81%)

12/24/20 Craig-Hallum
Celcuity price target raised to $19 from $16 at Craig-Hallum
06/25/20 BofA
Puma Biotechnology reinstated with an Underperform at BofA
06/25/20 BofA
Puma Biotechnology initiated with an Underperform at BofA
05/20/20 Cantor Fitzgerald
Puma Biotechnology price target raised to $16 from $14 at Cantor Fitzgerald
PBYI Puma Biotechnology
$10.62 /

-0.655 (-5.81%)

Earnings
Puma Biotechnology reports Q4 EPS (14c), consensus (29c) » 16:16
02/25/21
02/25
16:16
02/25/21
16:16
PBYI

Puma Biotechnology

$10.62 /

-0.655 (-5.81%)

Reports Q4 revenue…

Reports Q4 revenue $52.6M, consensus $52.79M.

ShowHide Related Items >><<
PBYI Puma Biotechnology
$10.62 /

-0.655 (-5.81%)

PBYI Puma Biotechnology
$10.62 /

-0.655 (-5.81%)

12/24/20 Craig-Hallum
Celcuity price target raised to $19 from $16 at Craig-Hallum
06/25/20 BofA
Puma Biotechnology reinstated with an Underperform at BofA
06/25/20 BofA
Puma Biotechnology initiated with an Underperform at BofA
05/20/20 Cantor Fitzgerald
Puma Biotechnology price target raised to $16 from $14 at Cantor Fitzgerald
PBYI Puma Biotechnology
$10.62 /

-0.655 (-5.81%)

Hot Stocks
Puma Biotechnology presents interim results from SUMMIT trial of neratinib » 08:03
01/29/21
01/29
08:03
01/29/21
08:03
PBYI

Puma Biotechnology

$11.79 /

-0.225 (-1.87%)

Puma Biotechnology…

Puma Biotechnology presented interim results from the ongoing SUMMIT trial of neratinib in the cohort of metastatic non-small cell lung cancer, or NSCLC, patients with epidermal growth factor, or EGFR, exon 18 mutations who have been previously treated with an EGFR targeted tyrosine kinase inhibitor, or TKI. The data were presented in an oral discussion at the 2020 World Conference on Lung Cancer, or WCLC. The Phase II SUMMIT basket trial is an open-label, multicenter, multinational study to evaluate the safety and efficacy of neratinib administered daily to patients who have solid tumors with activating EGFR exon 18 or HER2 mutations. In the EGFR exon 18 mutation cohort, patients with lung cancer with single or complex EGFR exon 18 mutations, who were EGFR TKI naive or were previously exposed to EGFR TKI, were enrolled into this study and received 240 mg of neratinib daily as a single agent. In this cohort of 11, patients had received a median of 2 prior lines of therapy in the metastatic setting before entering the trial. A total of 10 patients had been previously treated with an EGFR targeted tyrosine kinase inhibitor. The interim efficacy results from the trial showed that for the 10 evaluable patients who had previously been treated with an EGFR tyrosine kinase inhibitor, 6 patients experienced a partial response, which included 4 patients with a confirmed partial response. 8 patients experienced clinical benefit. The median duration of response was 7.5 months and the median progression-free survival was 9.1 months. The success criteria for both the 1st stage and the 2nd stage of the Simon's 2-stage design were met and enrollment in the 2nd stage of this cohort continues. The safety profile observed in the subgroup of patients with EGFR exon 18-mutated NSCLC showed that for the 11 patients who received neratinib in the trial, there were no reports of grade 3 or higher diarrhea. 4 patients reported grade 1 and 1 patient reported grade 2 diarrhea. No patients required a dose hold, dose reduction, hospitalization or permanently discontinued neratinib due to diarrhea.

ShowHide Related Items >><<
PBYI Puma Biotechnology
$11.79 /

-0.225 (-1.87%)

PBYI Puma Biotechnology
$11.79 /

-0.225 (-1.87%)

12/24/20 Craig-Hallum
Celcuity price target raised to $19 from $16 at Craig-Hallum
06/25/20 BofA
Puma Biotechnology reinstated with an Underperform at BofA
06/25/20 BofA
Puma Biotechnology initiated with an Underperform at BofA
05/20/20 Cantor Fitzgerald
Puma Biotechnology price target raised to $16 from $14 at Cantor Fitzgerald
PBYI Puma Biotechnology
$11.79 /

-0.225 (-1.87%)

Hot Stocks
Puma Biotechnology announces interim results from SUMMIT trial » 09:01
01/15/21
01/15
09:01
01/15/21
09:01
PBYI

Puma Biotechnology

$10.99 /

+0.17 (+1.57%)

Puma Biotechnology…

Puma Biotechnology announced interim results from the biliary tract cancers cohort of the ongoing SUMMIT trial of neratinib at the virtual 2021 Gastrointestinal Cancers Symposium hosted by the American Society of Clinical Oncology, or ASCO GI, that is currently taking place. The Phase II SUMMIT basket trial is an open-label, multicenter, multinational study that included a cohort evaluating the safety and efficacy of neratinib administered daily to patients who have HER2, or ERBB2, mutation-positive advanced biliary cancer. Patients received 240 mg of neratinib daily as a single agent. In this cohort of 25 patients, 11 patients had cholangiocarcinoma, 10 patients had cancer of the gallbladder and four patients had cancer of the ampulla of Vater. 24 patients had received prior systemic chemotherapy with a median of two prior lines of therapy before entering the trial. The efficacy results from the trial demonstrated that there were four patients with confirmed partial responses and an additional three patients who had stable disease lasting greater than or equal to16 weeks. This resulted in an objective response rate of 16% and a clinical benefit rate of 28%. The durations of response were 3.0 months, 3.7 months, and 4.7 months and additionally one patient with gallbladder cancer remains on treatment greater than 80 weeks. The safety profile of patients with biliary tract tumors is similar to that previously reported for patients treated with neratinib monotherapy and mandatory loperamide prophylaxis in the first two months; treatment was manageable, with 56% of patients experiencing some diarrhea, including 24% with grade 3 diarrhea. There were no episodes of grade 4 diarrhea, and no treatment discontinuations due to diarrhea. Four patients required neratinib dose reduction and one patient was hospitalized due to diarrhea.

ShowHide Related Items >><<
PBYI Puma Biotechnology
$10.99 /

+0.17 (+1.57%)

PBYI Puma Biotechnology
$10.99 /

+0.17 (+1.57%)

12/24/20 Craig-Hallum
Celcuity price target raised to $19 from $16 at Craig-Hallum
06/25/20 BofA
Puma Biotechnology reinstated with an Underperform at BofA
06/25/20 BofA
Puma Biotechnology initiated with an Underperform at BofA
05/20/20 Cantor Fitzgerald
Puma Biotechnology price target raised to $16 from $14 at Cantor Fitzgerald
PBYI Puma Biotechnology
$10.99 /

+0.17 (+1.57%)

Recommendations
Celcuity price target raised to $19 from $16 at Craig-Hallum » 08:14
12/24/20
12/24
08:14
12/24/20
08:14
CELC

Celcuity

$9.97 /

-0.75 (-7.00%)

, PBYI

Puma Biotechnology

$11.40 /

-0.12 (-1.04%)

Craig-Hallum analyst…

Craig-Hallum analyst Alexander Nowak raised the firm's price target on Celcuity (CELC) to $19 from $16 and reiterates a Buy rating on the shares. The company secured its third clinical trial collaboration, again with Puma Biotechnology (PBYI), but this time for metastatic breast cancer, Nowak tells investors in a research note. The new deal is another validation of Celcuity's companion diagnostic technology and its ability to identify responders when traditional diagnostic methods fail, says the analyst.

ShowHide Related Items >><<
PBYI Puma Biotechnology
$11.40 /

-0.12 (-1.04%)

CELC Celcuity
$9.97 /

-0.75 (-7.00%)

CELC Celcuity
$9.97 /

-0.75 (-7.00%)

12/24/20 H.C. Wainwright
Celcuity price target raised to $14 from $11 at H.C. Wainwright
05/18/20 Craig-Hallum
Celcuity assumed with a Buy at Craig-Hallum
05/11/20 Craig-Hallum
Celcuity assumed with a Buy at Craig-Hallum
05/08/20 H.C. Wainwright
Celcuity price target lowered to $11 from $19 at H.C. Wainwright
PBYI Puma Biotechnology
$11.40 /

-0.12 (-1.04%)

06/25/20 BofA
Puma Biotechnology reinstated with an Underperform at BofA
06/25/20 BofA
Puma Biotechnology initiated with an Underperform at BofA
05/20/20 Cantor Fitzgerald
Puma Biotechnology price target raised to $16 from $14 at Cantor Fitzgerald
PBYI Puma Biotechnology
$11.40 /

-0.12 (-1.04%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.